People · Operator
Named in public records as an officer, director or promoter · active 2019–2019 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Centerline Biomedical, Inc. | — | Biotechnology | Series B | $71.8M | $55.1M | 2019 |
Jim Zalar at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jim Zalar on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Akhil Saklecha | 1 | 3 |
| Karen Shanahan | 1 | 3 |
| Michael Whitman | 1 | 2 |
| Jai N. Gupta | 1 | 2 |
| Arnaud Marie | 1 | 1 |
| Indrani Egleston | 1 | 1 |
| Vikash K. Goel | 1 | 1 |
| Vinod K. Goel | 1 | 1 |
| Phil Rackliffe | 1 | 1 |
| Phil N. Rackliffe | 1 | 1 |
| Vikash N. Goel | 1 | 1 |
| Jim N. Zalar | 1 | 1 |
| Todd Schwarzinger | 1 | 1 |
| Mitch Wolf | 1 | 1 |
| Gulam Khan | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.